Thu, 22 Aug at 08:31
Donanemab contains antibodies that bind to a protein called amyloid, which builds up in the brain in the early stages of Alzheimer's disease. Unlike currently available treatments, which can only relieve symptoms, donanemab is a so-called 'disease-modifying' treatment that is designed to tackle the underlying disease.3 Jul 2024
.jpeg)